Skip to main content

Find Clinical Trials

Home
Conditions
Camrelizumab

Clinical trial condition

Camrelizumab

Explore clinical trials studying Camrelizumab. Study availability and eligibility vary by location and protocol.

6 public trials 5 recruiting studies

Refine in advanced search Browse all conditions

Camrelizumab trial results

Recruiting

Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

NCT07787273

Conditions: Camrelizumab, Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Locations: Hefei Cancer Hospital, Chinese Academy of Sciences Hefei, Anhui, China

The First Affiliated Hospital of Anhui Medical University Hefei, Anhui, China

View Trial Details

Recruiting

TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma

NCT06485466

Conditions: Apatinib, Camrelizumab, Transarterial Chemoembolization, +1 more
Locations: Sichuan Cancer Hospital and Research Institute Chengdu, Sichuan, China

View Trial Details

Recruiting

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

NCT05512481

Conditions: Acral Melanoma, Apatinib, Camrelizumab, +15 more
Locations: Beijing Cancer Hospital Beijing, Beijing Municipality, China

View Trial Details

Recruiting

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

NCT05475678

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +7 more
Locations: Henan cancer hospital Zhengzhou, Henan, China

View Trial Details

Recruiting

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

NCT06061276

Conditions: Adenocarcinoma, Camrelizumab, Carcinoma, +12 more
Locations: Sun Yat-sen University Cancer Center Guanzhou, Guangdong, China

View Trial Details

Not yet recruiting

A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT06276933

Conditions: Camrelizumab, Lung Cancer, Lung Diseases, +6 more
Locations: Not specified

View Trial Details